Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance

Stoke Therapeutics delivered mixed Q1 2026 results, beating EPS expectations at -$0.79 versus -$0.81 consensus but missing revenue at $6.23M versus $7.07M expected, with shares down 0.54% aftermarket. Management highlighted over $411M in cash, rapid EMPEROR phase III enrollment, and encouraging 4-year zorevunersen data supporting its long-term launch and labeling strategy. The core investment case remains intact, though near-term revenue execution remains weak.

Analysis

The market is still underestimating how much of STOK’s valuation is now a binary de-risking trade on execution rather than a traditional biotech cash-burn story. The long-duration dataset matters because it shifts the debate from “does the drug work?” to “can management translate a differentiated signal into label breadth, payer acceptance, and a launch curve?” That should compress financing risk for the next 12-18 months and support multiple expansion into the phase III readout window, even if the near-term revenue line remains noisy.

The cleaner second-order beneficiary is BIIB, not because it wins outright, but because a successful launch would validate the broader ASO category and expand payer willingness to reimburse high-priced, disease-modifying rare neuro assets. The competitive threat is more subtle: if zorevunersen is priced like a seizure drug instead of a disease-modifying asset, the entire rare-epilepsy analog set rerates lower; if it is priced like a chronic, multi-domain therapy, it creates a new anchor for premium reimbursement in ultra-orphan neurology.

The main risk is timing asymmetry. The stock can rally on every incremental de-risking milestone over the next 6-9 months, but the setup remains vulnerable to one bad readout in mid-2027 or a weak payer response that caps label ambition. The biggest short-term catalyst is not the Q1 beat/miss; it is continued enrollment completion and whether management can keep the FDA-label narrative alive without overpromising on secondaries.

Contrarian view: the move is likely underdone if investors are still modeling this as a small-cap R&D burn with a binary phase III. The stronger signal is that management is already selling the commercial bridge before approval, implying internal confidence that the launch audience is concentrated and reachable. That makes this more like a late-stage platform normalization story than a classic pre-revenue biotech, which argues for a higher base multiple than the market likely assigns today.

Key Decisions for Investors

• Long STOK into the next 1-3 months on any consolidation; use a phased build with a 6-9 month horizon for de-risking into enrollment completion and NDA start, targeting a rerate if the market begins pricing label breadth rather than just binary readout risk.
• Buy STOK Jan-2027 calls or call spreads to express upside into the mid-2027 catalyst while capping downside; best risk/reward if implied vol stays elevated but not euphoric.
• Pair trade: long STOK / short a basket of lower-quality pre-commercial biotech names with weaker cash runways; the relative thesis is that STOK has already crossed the financing-risk threshold while many peers have not.
• Add BIIB on weakness as a category-validation hedge to STOK upside; if zorevunersen strengthens the ASO framework, BIIB benefits from sentiment spillover and payer familiarity with chronic rare-neurology reimbursement.
• Avoid chasing the stock after sharp catalyst spikes; if the share price runs ahead of trial timelines, trim 25-30% and keep the remainder for the more important label-shaping and payer-education milestones over the next 2-3 quarters.